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Fungal infections in the central nervous system (CNS) are associated with significant morbidity and death. Transient fungemia
in immunocompetent patients without any other risk factors for fungemia has been suggested as a possible mechanism that may
lead to serious fungal ventriculoperitoneal (VP) shunt infections, but evidence is lacking. The clinical spectrum, diagnosis, and
optimal therapy of Cyberlindnera fabianii infections remain to be determined. We describe the first case of CNS infection due to C.
fabianii that occurred in an immunocompetent adult with a VP shunt. Spontaneous translocation with yeast that is not part of the
normal gastrointestinal flora in the setting of ingestion of multiple servings of a fermentation product was the likely source from
which Cyberlindnera fabianii gained entrance into the VP shunt system, causing meningitis in this patient. The authors conclude
that, in view of the high morbidity associated with yeast infection of the CNS, long-term antifungal therapy should be strongly
considered in cases where the VP shunt cannot be completely removed. Transient fungemia may lead to invasive disease in an
immunocompetent host with VP shunt, even in the absence of any other risk factors for fungemia and even after remote placement
of the VP shunt.
1. Introduction
Ventriculoperitoneal (VP) shunt is one of the most common
neurosurgical procedures. Although infection is a common
complication of shunt procedures, fungi are rarely implicated
in VP shunt infections [1–4]. Transient fungemia and sec-
ondary colonization of VP shunts in the absence of other
risk factors for fungemia have been suggested as a possible
mechanism of fungal VP infections [5] but definite evidence
is lacking. The heterothallic yeast Cyberlindnera fabianii,
previously known as Hansenula fabianii, Pichia fabianii, and
Lindnera fabianii [6], belongs to the phylumAscomycota and
is a member of the same order (Saccharomycetales) as other
medically important yeasts such as Candida spp. Results
from a recent phylogenetic analysis based on large and small
subunit ribosomal ribonucleic acids (rRNA) and translation
elongation factor-1𝛼 gene led to separation of the genus
Cyberlindnera from its parental genus Williopsis [7]. Only 14
infections due to this organism have been reported [8–16].
Of the 14 cases, 10 involved fungemia [9–16] and 4 were
limited to the genitourinary tract [8, 16]. Herein, we report
the first case of central nervous system (CNS) infection due
to C. fabianii that also suggests that transient fungemia in
immunocompetent patients without any other risk factors for
fungemia and with a remote history of VP placement may
lead to serious fungal VP shunt infections.
2. Case Report
A 49-year-old Vietnamese-American woman with history
of depression presented to our institution with confusion,
headache, and difficulty in walking. Her medical history
was significant for a ruptured anterior communicating artery
aneurysm 10 years earlier that required craniotomy, clip-
ping, and placement of a ventriculoperitoneal (VP) shunt.
Four months prior to her presentation, she underwent a
second craniotomy for clipping of a right middle cerebral
artery aneurysm that was found on surveillance imaging.
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On presentation, she denied fever, chills, neck stiffness,
photophobia, or head trauma. She was afebrile. The rest of
her vital signs and physical examination, including neuro-
logic examination, were unremarkable. Laboratory data was
significant for a white blood cell count of 7810 cells/mm3 with
66.6% polymorphonuclear cells. Other laboratory data were
within normal limits. Imaging (computed tomography) of the
neck, chest, and abdomen showed hydrocephalus and the VP
shunt in position without kinks.
Shortly after presentation, the patient underwent urgent
neurosurgery for VP shunt revision. Close examination of
the shunt during surgery revealed an obstructed valve, which
was replaced. The intraventricular portion of the shunt
could not be removed for inspection due to tissue scarring.
Postoperatively, the patient became somnolent and was
intubated for airway protection. Cerebrospinal fluid (CSF)
studies from samples taken intraoperatively were significant
for 29 red blood cells per mm3, 11 white blood cells per
mm3 (33% neutrophils, 55% lymphocytes, and 12% mono-
cytes), protein 65mg/dL, and glucose 29mg/dL. CSF Gram
stain demonstrated budding yeast. Other studies, including
serum and CSF cryptococcal antigen (ImmunoMycologics,
Inc., Norman, OK), Coccidioides IgM and IgG antibodies
(Meridian Bioscience, Inc., Cincinnati, OH), and bacterial
and fungal blood cultures, were negative.
She was started empirically on intravenous liposomal
amphotericin B at a dose of 5mg/kg daily and oral flucytosine
at a dose of 25mg/kg four times daily on hospital day 1.
Her mental status improved on antifungal therapy and she
was extubated on hospital day 3. Though fungal CSF culture
from hospital day 3 showed growth of a yeast after 10 days of
incubation, CSF specimens collected on hospital days 5 and 7
were negative for microorganisms, both by fungal and Gram
stain, and culture. A second neurosurgical procedure was
performed, but the deep intraventricular portion of the VP
shunt still could not be removed due to severe tissue scarring.
Instead, that end was ligated, the remainder of the shunt was
removed, and a new shunt was placed on the contralateral
side.
The yeast isolated from CSF collected during the first
neurosurgical procedure demonstrated lush growth after 24
hours of incubation on inhibitory mold agar (IMA) [17] at
30∘C. Two colonymorphotypes (smooth and rough off-white
colonies) were observed. Wet mount preparation from both
morphotypes demonstrated budding yeast cells with pseu-
dohyphae (Figure 1). Both morphotypes were identified by a
Vitek MSMatrix-Assisted Laser Desorption/Ionization Time
of Flight (MALDI TOF) mass spectrometer (bioMe´rieux,
Inc., Durham, NC) as Candida boidinii. API 20C System
(bioMe´rieux, Inc., Durham, NC) identification yielded pro-
files that were nondescriptive. A definitive identification of
C. fabianii for both morphotypes was achieved through
sequencing of the D1/D2 region of the large subunit of 28S
ribosomal RNA gene and internal transcribed spacer (ITS)
region [18]. Antifungal susceptibility testing was performed
according toCLSI standards by brothmicrodilution in RPMI,
in panels prepared in-house [19]. Antifungal minimum
inhibitory concentrations (MIC) for fluconazole, flucytosine,
Figure 1: Wet mount preparation of C. fabianii from growth on
IMA, demonstrating budding yeast cells and elongated pseudohy-
phae.
and amphotericin B were 2.0, <0.12, and 2.0mg/L, respec-
tively.
Follow-up detailed history for possible environmental
exposures revealed that the patient had ingested multiple
servings of cơm rưu, a traditional Vietnamese dessert
prepared by fermenting rice, 5–7 days before the onset of
illness. The patient denied ingestion of raw milk and cheese.
The patient was discharged home after 11 days, still
receiving intravenous liposomal amphotericin B and oral
flucytosine. After 19 days of antifungals, she developed acute
kidney injury and her regimen was changed to monotherapy
with oral fluconazole. She developed painful cheilitis with
fluconazole 800mg daily and thus had her dose adjusted to
400mg. At 6-month follow-up, she was feeling better and had
returned to baseline function. She will continue fluconazole
indefinitely to prevent recrudescence of her infection in the
setting of retained VP shunt components.
3. Discussion
Fungal meningitis is an uncommon but serious condition
affecting neurosurgical patientswithVP shunts [1, 4]. Patients
tend to present with fever and symptoms of shunt malfunc-
tion, such as headache, nausea, and altered mental status
[1, 4]. In particular, Candida spp. have been identified as the
cause of ∼1% of VP shunt infections [1–4]. Up to 77% of
Candida VP shunt infections develop within three months
of shunt manipulation, suggesting inoculation of the organ-
ism during surgery [1–4]. Other risk factors include recent
abdominal surgery, bowel perforation, use of broad-spectrum
antibiotics, steroids, vascular catheters, prior or concurrent
meningitis, and CSF leak [1, 4]. Transient fungemia in the
absence of the above risk factors has been suggested as
a mechanism that may lead to VP shunt fungal infection
[5], but evidence is lacking. The current case demonstrates
that transient fungemia with a yeast that is not part of the
normal gastrointestinal flora may has occurred in the setting
of ingestion of multiple servings of a fermentation product
despite lack of known bowel disease. Thus, this case provides
indirect evidence that supports the hypothesis that transient
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fungemia in immunocompetent patients without any other
risk factors for fungemia may lead to serious fungal VP shunt
infections, even with a remote history of VP placement.
Candida fabianii is an environmental yeast with similar-
ities to Candida spp. Members of the genus Cyberlindnera
exhibit phenotypic traits shared by members of the genera
Pichia, Issatchenkia, and Williopsis, including production of
ubiquinone CoQ-7 and inability to utilize methanol [7]. As
with other heterothallic ascomycetous yeasts, C. fabianii is
capable of sexual reproduction in which an ascus is formed
containing small hat-shaped ascospores [20]. Despite being
not typically performed in a clinical laboratory, organisms in
this group can be induced to form ascospores using special
sporulation media such as V8 agar and Gorodkowa agar
[21]. Identification of this particular yeast species can be
problematic [16]. Commercial identification platforms such
as Vitek 2 with ID 32C system have been shown to incorrectly
identify C. fabianii as Candida pelliculosa or Candida utilis
[10]. Although MALDI-TOF has been shown in a recent
report to be able to identify clinically relevant Candida spp.,
it failed to identify C. fabianii, whose spectral profile was
not included in the Saramis reference database used with
the Vitek MS [22]. Antifungal susceptibility testing may be
performed on this organism using broth dilution method as
for other yeasts, though there are currently no interpretive
criteria [23].
Infections due to C. fabianii are extremely rare and have
to date not involved the central nervous system. Details of the
14 reported cases are summarized in Table 1. Cases have been
described in 9 neonates and 5 adults (average age of 48.6,
range of 40–57). Three cases developed in individuals who
were not known to be immunocompromised [9, 10, 14].Three
patients suffered from concurrent colitis [9, 11, 14]. Nine of ten
(90%) fungemias developed in the setting of broad-spectrum
antibiotics [9–16]. In all cases, C. fabianii was isolated by
culture. In 13 of 14 cases (92.9%), species identification was
confirmed by molecular sequencing. Antifungal susceptibil-
ity varies, with 10 of 14 (71.4%) cases involving isolates with
MICs ≤ 2 𝜇g/mL for fluconazole [8–11]. Mlinaric´-Missoni
et al. recently described the susceptibility profiles of the 44
isolates (from six patients) of C. fabianii to amphotericin
B, flucytosine, triazoles, and echinocandins and found a
higher proportion of nonsusceptible isolates of C. fabianii
for micafungin compared with the other tested antifungals
[16]. No in vitro resistance to amphotericin B, flucytosine,
fluconazole, itraconazole, or voriconazole was observed [16].
Treatments have been various, with amphotericin B,
fluconazole, and caspofungin all used successfully. In two
cases (14.3%), major surgery was required for source control
[10, 13]. Microbiological and clinical cure was achieved in 11
cases (78.6%) [8, 10, 11, 13, 14, 16]. In the remaining three cases,
the infected patient did not survive [9, 12, 15].
Pichia species are often found in raw milk, cheese, and
traditional fermented products and a case of Pichia anomala
(Candida pelliculosa) fungemia from ingestion of raw milk
and yogurt has been published [24]. Candida fabianii has
been isolated from fermentation products [25] and home-
made alcoholic beverages [26]. We suspect our patient
acquired C. fabianii via ingestion of cơm rưu, a traditional
Vietnamese dessert made from the fermentation of rice.
We hypothesize that C. fabianii may have inoculated the
peritoneal terminus of her VP shunt via translocation from
the gut, either directly across the peritoneal space or by
transient fungemia. This hypothesis is supported by the
predilection of C. fabianii for neonates—whose gut mucosal
immunity is undeveloped—and adults with colitis. A similar
mechanismof infection has been proposed for Saccharomyces
cerevisiae, which has caused fungemia in immunocompetent
individuals ingesting the organism as a probiotic [27]. This
case suggests for the first time that C. fabianii may lead
to invasive disease in an immunocompetent host with a
remote history of VP shunt placement after ingestion of
commercially available fermentation products.
Given the rarity of C. fabianii infections, no guidelines
are available to direct treatment. Decisions regarding anti-
fungal therapy must be individualized. Amphotericin B and
flucytosine were chosen initially, prior to determination of
the species of the yeast and its antifungal susceptibility, based
on clinical guidelines for central nervous system candidiasis
[28]. By the time C. fabianii was identified, the patient had
already recovered symptomatically, achieved microbiologic
cure, and been transitioned to oral fluconazole for mainte-
nance. Clinical studies of adults with cryptococcal meningitis
have shown that a dose of fluconazole 400mg daily achieves
average CSF concentrations of 25.1mg/L, a concentration
at least 10 times higher than the MICs of our two isolates
[29]. Further, there is a precedent for the use of fluconazole
400mg daily for maintenance therapy in the management
of cryptococcal meningitis [30]. In other instances of fungal
meningitis, removal of indwelling devices such as VP shunts
is considered standard of care [31, 32]. Unfortunately, compo-
nents of our patient’s infectedVP shunt remain in place.Thus,
she will likely require lifelong antifungal therapy. If recurrent
infection develops, repeat susceptibility testingwill need to be
performed, as at least one case ofC. fabianii has been reported
to develop an elevated MIC to fluconazole and voriconazole
during prolonged therapy [10]. In a case series of 6 cases
of C. fabianii infection, fluconazole administration either
prophylactically or therapeutically did not lead to resolution
of the infection in 50% of the patients [16]. Thus, every
effort should be made for complete removal of VP shunts
infected with C. fabianii since in certain cases long-term oral
suppression therapy with an azole may not be an option.
4. Conclusions
Clinicians should be aware of the clinical presentation, diag-
nostic methods, and therapeutic options for treatment of C.
fabianii infection, as this organismmay cause life-threatening
infections including CNS infections. Transient fungemiamay
lead to invasive disease in an immunocompetent host with
VP shunt, even in the absence of any other risk factors for
fungemia and even after remote placement of the VP shunt.
In view of the high morbidity associated with yeast infection
of the CNS, long-term antifungal therapy should be strongly
considered in cases where the VP shunt cannot be completely
removed.
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